The objective of this study was to develop caffeine citrate orally disintegrating tablet (ODT) formulations utilizing hot-melt extrusion technology and evaluate the ability of the formulation composition to mask the unpleasant bitter taste of the drug using in vitro and in vivo methods. Ethylcellulose, along with a suitable plasticizer, was used as a polymeric carrier. Pore forming agents were incorporated into the extruded matrix to enhance drug release. A modified screw configuration was applied to improve the extrusion processability and to preserve the crystallinity of the API. The milled extrudates were subjected to dissolution testing in an artificial salivary fluid and investigations using e-tongue, to assess the extent of masking of bitter taste of the API. There was an insignificant amount of drug released from the formulation in the salivary medium while over 80% of drug released within 30 min in 0.1N HCl. ODTs were also developed with the extrudate mixed with mannitol and crospovidone. The quality properties such as friability and disintegration time of the ODTs met the USP specifications. The lead extrudate formulations and the ODTs prepared using this formulation were subjected to human gustatory evaluation. The formulations were found to mask the unpleasant taste of caffeine citrate significantly.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543393PMC
http://dx.doi.org/10.1016/j.ijpharm.2015.04.030DOI Listing

Publication Analysis

Top Keywords

caffeine citrate
12
formulations utilizing
8
extrusion technology
8
mask unpleasant
8
bitter taste
8
drug released
8
development taste
4
taste masked
4
masked caffeine
4
formulations
4

Similar Publications

Background: Minimizing the duration of mechanical ventilation is one of the most important therapeutic goals during the care of preterm infants at neonatal intensive care units (NICUs). The rate of extubation failure among preterm infants is between 16% and 40% worldwide. Numerous studies have been conducted on the assessment of extubation suitability, the optimal choice of respiratory support around extubation, and the effectiveness of medical interventions.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines how variations in adenosine and dopamine receptor genes, along with clinical factors, affect how preterm infants respond to caffeine citrate treatment for apnea of prematurity (AOP).
  • It analyzed data from 221 preterm infants, identifying 160 as responders to treatment and 61 as non-responders, while genotyping 22 genetic polymorphisms to compare outcomes.
  • Findings showed that non-responders had higher rates of complications and specific genetic variations linked to poor response, while greater gestational age was identified as a protective factor; a predictive nomogram for treatment response was also developed.
View Article and Find Full Text PDF

Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia.

Stroke

November 2024

Department of Pediatrics (J.K.M., Y.W., J.H., A.I., C.H., R.S.H., C.V., H.M., J.L.-B., J.R.F., D.M.F., E.M.), University of California San Francisco.

Article Synopsis
  • Neonatal hypoxic-ischemic encephalopathy primarily impacts low- and middle-income countries, with therapeutic hypothermia often proving ineffective, highlighting a need for earlier treatment strategies.
  • A study involved administering perinatal caffeine to near-term lambs undergoing severe hypoxia-ischemia, assessing its pharmacokinetics, safety, and efficacy in improving outcomes.
  • Caffeine administration enhanced neurodevelopmental results and decreased inflammation and gray matter damage, suggesting it could be a viable treatment for affected neonates compared to previous studies on other medications.
View Article and Find Full Text PDF

Neonatal encephalopathy due to suspected hypoxic ischemic encephalopathy: pathophysiology, current, and emerging treatments.

World J Pediatr

November 2024

SAMRC Extramural Unit for Stem Cell Research and Therapy, Department of Immunology, Faculty of Health Sciences, Institute for Cellular and Molecular Medicine, University of Pretoria, Room 5-64, Level 5, Pathology Building, 15 Bophelo Road (Cnr. Steve Biko and Dr. Savage Streets), Prinshof Campus, Gezina, Pretoria, South Africa.

Background: Neonatal encephalopathy (NE) due to suspected hypoxic-ischemic encephalopathy (HIE), referred to as NESHIE, is a clinical diagnosis in late preterm and term newborns. It occurs as a result of impaired cerebral blood flow and oxygen delivery during the peripartum period and is used until other causes of NE have been discounted and HIE is confirmed. Therapeutic hypothermia (TH) is the only evidence-based and clinically approved treatment modality for HIE.

View Article and Find Full Text PDF

Background: Considerable interindividual variability for the pharmacokinetics of caffeine in preterm infants has been demonstrated, emphasizing the importance of personalized dosing. This study aimed to develop and apply a repository of currently published population pharmacokinetic (PopPK) models of caffeine in preterm infants to facilitate model-informed precision dosing (MIPD).

Research Design And Methods: Literature search was conducted using PubMed, Embase, Scopus, and Web of Science databases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!